Acid Reducer Non-Prescription Strength Disease Interactions

Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.

Ranitidine may rarely precipitate acute porphyria attacks and should be avoided in patients with a history of acute porphyria.

Ranitidine is partially removed by hemodialysis and should be administered after dialysis.

Ranitidine is partially metabolized by the liver. Although dosage reductions are generally not necessary, therapy with ranitidine should be administered cautiously in patients with liver disease. Elevated ALT (SGPT) has been observed in patients receiving ranitidine intravenously at dosages greater than those normally recommended for 5 days or more.

Zantac (brand of ranitidine) 150 EFFERdose tablets and granules both contain 16.84 mg of phenylalanine per each 150 mg of ranitidine. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

Ranitidine is primarily eliminated by the kidney. Although the drug is generally well-tolerated, the daily dosage should initially be reduced in patients with moderate to severe renal impairment (CrCl < 50 mL/min). If necessary, the daily dosage may be increased with caution.